David Malcom Rodman Sells 14,056 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock

Posted by Brenda Bartman on May 15th, 2026

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) insider David Malcom Rodman sold 14,056 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $28.58, for a total value of $401,720.48. Following the transaction, the insider owned 63,443 shares of the company’s stock, valued at approximately $1,813,200.94. This trade represents a 18.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Malcom Rodman also recently made the following trade(s):

On Tuesday, May 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $29.36, for a total value of $186,377.28.
On Monday, May 11th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $29.71, for a total value of $64,500.41.
On Friday, April 17th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $31.33, for a total value of $13,033.28.
On Wednesday, April 15th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.66, for a total value of $175,585.68.
On Monday, April 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.54, for a total value of $373,099.32.
On Thursday, April 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.38, for a total value of $59,414.60.
On Thursday, March 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.37, for a total value of $173,744.76.
On Friday, March 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.26, for a total value of $369,163.08.
On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.84, for a total value of $58,269.64.
On Tuesday, February 17th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.59, for a total value of $11,505.03.

Mineralys Therapeutics Price Performance

Shares of MLYS opened at $27.27 on Friday. The business’s fifty day moving average price is $27.09 and its 200 day moving average price is $32.67. Mineralys Therapeutics, Inc. has a 12-month low of $12.59 and a 12-month high of $47.65. The stock has a market capitalization of $2.25 billion, a PE ratio of -13.30 and a beta of 0.49.

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.04. As a group, research analysts anticipate that Mineralys Therapeutics, Inc. will post -2.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on MLYS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Tuesday, April 21st. Bank of America raised their target price on Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a research note on Friday, March 13th. HC Wainwright set a $56.00 price target on Mineralys Therapeutics and gave the company a “buy” rating in a report on Tuesday, March 10th. TD Cowen started coverage on Mineralys Therapeutics in a report on Monday, April 27th. They set a “buy” rating on the stock. Finally, Jefferies Financial Group reissued a “hold” rating and set a $30.00 price target on shares of Mineralys Therapeutics in a report on Friday, March 13th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $49.33.

Get Our Latest Stock Analysis on Mineralys Therapeutics

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of MLYS. State Street Corp grew its holdings in Mineralys Therapeutics by 144.4% during the fourth quarter. State Street Corp now owns 3,184,999 shares of the company’s stock worth $115,584,000 after acquiring an additional 1,881,976 shares during the period. Farallon Capital Management LLC purchased a new position in Mineralys Therapeutics in the 3rd quarter worth about $63,442,000. Price T Rowe Associates Inc. MD increased its stake in Mineralys Therapeutics by 6,097.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,325,120 shares of the company’s stock worth $48,089,000 after purchasing an additional 1,303,737 shares in the last quarter. Holocene Advisors LP purchased a new position in Mineralys Therapeutics in the 3rd quarter worth about $45,708,000. Finally, Janus Henderson Group PLC increased its stake in Mineralys Therapeutics by 6,012.8% in the 4th quarter. Janus Henderson Group PLC now owns 1,213,265 shares of the company’s stock worth $44,005,000 after purchasing an additional 1,193,417 shares in the last quarter. 84.46% of the stock is owned by institutional investors and hedge funds.

Mineralys Therapeutics Company Profile

(Get Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.